{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:21:09Z","timestamp":1791174069638,"version":"4.1.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["VHRM"],"DOI":"10.2147\/vhrm.s75215","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T17:44:21Z","timestamp":1419356661000},"page":"9","source":"Crossref","is-referenced-by-count":6,"title":["Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease"],"prefix":"10.2147","author":[{"given":"Peter","family":"Toth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,12]]},"container-title":["Vascular Health and Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=23014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:16:52Z","timestamp":1477851412000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/overview-of-saxagliptin-efficacy-and-safety-in-patients-with-type-2-di-peer-reviewed-article-VHRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/vhrm.s75215","relation":{},"ISSN":["1178-2048"],"issn-type":[{"value":"1178-2048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}